SCHEDULE: Cadian Capital Discloses 3.5% Stake in MaxCyte

Cadian Capital Management and its affiliates reported a 3.5% beneficial ownership stake in MaxCyte, Inc. as of December 31, 2025.

Summary

• Cadian Capital Management, LP, Cadian Capital Management GP, LLC, and Eric Bannasch (collectively, the "Reporting Persons") beneficially owned 3,683,052 shares of MaxCyte, Inc. Common Stock.
• This ownership represents approximately 3.5% of MaxCyte, Inc.'s outstanding Common Stock, based on 106,674,011 shares outstanding as of November 7, 2025.
• The shares are held by Cadian Master Fund L.P. and Cadian Opportunities Master Fund LP, advisory clients of Cadian Capital Management, LP.
• The Reporting Persons exercise shared voting and shared dispositive power over all 3,683,052 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. It is a standard disclosure of a passive ownership stake and does not indicate any significant positive or negative developments for the company or the investor.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures by passive investors holding less than 20% of a company's stock, indicating a long-term, non-activist investment strategy. This filing updates Cadian Capital's position in MaxCyte, a biotechnology company, within the broader context of institutional investment in the life sciences sector.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake, confirming Cadian Capital Management's continued passive investment in MaxCyte, Inc.

Key Dates

Keywords

MaxCyte Inc., Cadian Capital Management, Beneficial Ownership, Schedule 13G, Common Stock, Investment Management, Equity Stake